Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Melanie T. Rebechi & Keith W. Pratz. (2017) Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression. Leukemia & Lymphoma 58:9, pages 2040-2050.
Read now
Read now
Angela Y.-C. Tan, Stephen Q. Wong, Charlotte Guldborg Nyvold, Dennis A. Carney, Andrew Wei, John F. Seymour, Peter Hokland, Westerman & Alexander Dobrovic. (2012) Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis. Leukemia & Lymphoma 53:6, pages 1225-1229.
Read now
Read now
Sun-Young Han & Young-Won Chin. (2011) A FLT3-inhibitory constituent from the rhizomes of Anemarrhena asphodeloides. Journal of Enzyme Inhibition and Medicinal Chemistry 26:3, pages 445-448.
Read now
Read now
Articles from other publishers (33)
Srimanta Patra, Prakash P. Praharaj, Daniel J. Klionsky & Sujit K. Bhutia. (2022) Vorinostat in autophagic cell death: A critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention. Drug Discovery Today 27:1, pages 269-279.
Crossref
Crossref
Delphine Verbeke, Olga Gielen, Kris Jacobs, Nancy Boeckx, Kim De Keersmaecker, Johan MaertensAnne UyttebroeckHeidi SegersJan Cools. (2019) Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia. HemaSphere 3:6, pages e310.
Crossref
Crossref
Manuela Schmidinger & Romano Danesi. (2018) Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. The Oncologist 23:3, pages 306-315.
Crossref
Crossref
Richard M. Stone, Paul W. Manley, Richard A. Larson & Renaud Capdeville. (2018) Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Advances 2:4, pages 444-453.
Crossref
Crossref
Hyo Jeong Lee, Jungeun Lee, Pyeonghwa Jeong, Jungil Choi, Juhwa Baek, Su Jin Ahn, Yeongyu Moon, Jeong Doo Heo, Young Hee Choi, Young-Won Chin, Yong-Chul Kim & Sun-Young Han. (2017) Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia. Oncotarget 9:1, pages 924-936.
Crossref
Crossref
Mohamed E. Salama & Ronald Hoffman. 2018. Hematology. Hematology
763
773
.
Hasan Mahmud, Frank J.G. Scherpen, Tiny Meeuwsen de Boer, Harm-Jan Lourens, Caroline Schoenherr, Matthias Eder, Michaela Scherr, Victor Guryev & Eveline S. De Bont. (2017) Peptide microarray profiling identifies phospholipase C gamma 1 (PLC-γ1) as a potential target for t(8;21) AML. Oncotarget 8:40, pages 67344-67354.
Crossref
Crossref
Betty Lam, Yasuyoshi Arikawa, Joshua Cramlett, Qing Dong, Ron de Jong, Victoria Feher, Charles E. Grimshaw, Pamela J. Farrell, Isaac D. Hoffman, Andy Jennings, Benjamin Jones, Jennifer Matuszkiewicz, Joanne Miura, Hiroshi Miyake, Srinivasa Reddy Natala, Lihong Shi, Masashi Takahashi, Ewan Taylor, Corey Wyrick, Jason Yano, Jonathan Zalevsky & Zhe Nie. (2016) Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). Bioorganic & Medicinal Chemistry Letters 26:24, pages 5947-5950.
Crossref
Crossref
Hye Jin Chung, Majid Rasool Kamli, Hyo Jeong Lee, Jae Du Ha, Sung Yun Cho, Jongkook Lee, Jae Yang Kong & Sun-Young Han. (2014) Discovery of quinolinone derivatives as potent FLT3 inhibitors. Biochemical and Biophysical Research Communications 445:3, pages 561-565.
Crossref
Crossref
Xiaochuan Yang, Amy Sexauer & Mark Levis. (2014) Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. British Journal of Haematology 164:1, pages 61-72.
Crossref
Crossref
Young-Won Chin, Jae Yang Kong & Sun-Young Han. (2013) Flavonoids as receptor tyrosine kinase FLT3 inhibitors. Bioorganic & Medicinal Chemistry Letters 23:6, pages 1768-1770.
Crossref
Crossref
Ho-June Lee, Gabriele Schaefer, Timothy P. Heffron, Lily Shao, Xiaofen Ye, Steve Sideris, Shiva Malek, Emily Chan, Mark Merchant, Hank La, Savita Ubhayakar, Robert L. Yauch, Valentina Pirazzoli, Katerina Politi & Jeff Settleman. (2013) Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M. Cancer Discovery 3:2, pages 168-181.
Crossref
Crossref
David A. Sweetser & Howard J. Weinstein. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
355
373
.
Hugo F Fernandez. (2012) Targeted therapy in acute myeloid leukemia: aim with caution. International Journal of Hematologic Oncology 1:2, pages 99-101.
Crossref
Crossref
R Swords, C Freeman & F Giles. (2012) Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 26:10, pages 2176-2185.
Crossref
Crossref
Babu P. Mohan, Gee‐fung How, Yvonne Loh & Yeh‐ching Linn. (2011) Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3‐internal tandem duplication positive acute myeloid Leukaemia. British Journal of Haematology 157:1, pages 131-132.
Crossref
Crossref
David K. Heidary, George Huang, Diane Boucher, Jianguo Ma, Cornelia Forster, Ron Grey, Jinwang Xu, Michael Arnost, Deborah Choquette, Guanjing Chen, Jie-Hua Zhou, Yung-Mae Yao, Edward D. Ball, Mark Namchuk, Robert J. Davies & Greg Henkel. (2012) VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia. Journal of Medicinal Chemistry 55:2, pages 725-734.
Crossref
Crossref
Shinichiro Takahashi. (2011) Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. Journal of Hematology & Oncology 4:1.
Crossref
Crossref
Jenna VanLiere Canzoniero, Bhavana Bhatnagar, Maria R. Baer & Ivana Gojo. (2011) Upfront Therapy of Acute Myeloid Leukemia. Current Oncology Reports 13:5, pages 361-370.
Crossref
Crossref
Takashi Sato, Xiaochuan Yang, Steven Knapper, Paul White, B. Douglas Smith, Steven Galkin, Donald Small, Alan Burnett & Mark Levis. (2011) FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117:12, pages 3286-3293.
Crossref
Crossref
Emma Scott, Elizabeth Hexner, Alexander Perl & Martin Carroll. (2010) Targeted Signal Transduction Therapies in Myeloid Malignancies. Current Oncology Reports 12:6, pages 358-365.
Crossref
Crossref
E Weisberg, M Sattler, A Ray & J D Griffin. (2010) Drug resistance in mutant FLT3-positive AML. Oncogene 29:37, pages 5120-5134.
Crossref
Crossref
Ibrahim Mustafa El-Deeb, Dong-Keun Han, In-Tae Kim & So-Ha Lee. (2010) New Phenylaminopyrimidine (PAP) Anticancer Lead Compound with High Efficacy: Design, Synthesis, and in vitro Screening. Bulletin of the Korean Chemical Society 31:7, pages 1848-1858.
Crossref
Crossref
Sun‐Young Han, Jin Hee Ahn, Chan Young Shin & Sang‐Un Choi. (2010) Effects of indirubin derivatives on the FLT3 activity and growth of acute myeloid leukemia cell lines. Drug Development Research 71:4, pages 221-227.
Crossref
Crossref
Muneyoshi Futami & Seth J. Corey. 2010. Handbook of Cell Signaling. Handbook of Cell Signaling
2821
2829
.
Dan Jones. 2010. Neoplastic Hematopathology. Neoplastic Hematopathology
611
626
.
Weina Chen, Sergej Konoplev, L. Jeffrey Medeiros, Hartmut Koeppen, Vasiliki Leventaki, Saroj Vadhan-Raj, Dan Jones, Hagop M. Kantarjian, Brunangelo Falini & Carlos E. Bueso-Ramos. (2009)
Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with
FLT3
internal tandem duplication and
NPM1
mutation
. Cancer 115:23, pages 5481-5489.
Crossref
Crossref
Miguel Sanz, Alan Burnett, Francesco Lo-Coco & Bob Löwenberg. (2009) FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Current Opinion in Oncology 21:6, pages 594-600.
Crossref
Crossref
Zhuang Zuo, Pranil Chandra, Yong Hannah Wen & Hartmut Koeppen. (2009) Molecular diagnostics of acute myeloid leukaemia. Diagnostic Histopathology 15:11, pages 531-539.
Crossref
Crossref
Elaine R. Mardis, Li Ding, David J. Dooling, David E. Larson, Michael D. McLellan, Ken Chen, Daniel C. Koboldt, Robert S. Fulton, Kim D. Delehaunty, Sean D. McGrath, Lucinda A. Fulton, Devin P. Locke, Vincent J. Magrini, Rachel M. Abbott, Tammi L. Vickery, Jerry S. Reed, Jody S. Robinson, Todd Wylie, Scott M. Smith, Lynn Carmichael, James M. Eldred, Christopher C. Harris, Jason Walker, Joshua B. Peck, Feiyu Du, Adam F. Dukes, Gabriel E. Sanderson, Anthony M. Brummett, Eric Clark, Joshua F. McMichael, Rick J. Meyer, Jonathan K. Schindler, Craig S. Pohl, John W. Wallis, Xiaoqi Shi, Ling Lin, Heather Schmidt, Yuzhu Tang, Carrie Haipek, Madeline E. Wiechert, Jolynda V. Ivy, Joelle Kalicki, Glendoria Elliott, Rhonda E. Ries, Jacqueline E. Payton, Peter Westervelt, Michael H. Tomasson, Mark A. Watson, Jack Baty, Sharon Heath, William D. Shannon, Rakesh Nagarajan, Daniel C. Link, Matthew J. Walter, Timothy A. Graubert, John F. DiPersio, Richard K. Wilson & Timothy J. Ley. (2009) Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. New England Journal of Medicine 361:11, pages 1058-1066.
Crossref
Crossref
W Korver, X Zhao, S Singh, C Pardoux, J Zhao, M L Guzman, S Sen, S Yonkovich, S Liu, X Zhan, N Tomasevic, C Zhou, D Gros, C T Jordan, J Gotlib, E D Hsi & A Abo. (2009) Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia 23:9, pages 1587-1597.
Crossref
Crossref
Ellen Weisberg, Rosemary Barrett, Qingsong Liu, Richard Stone, Nathanael Gray & James D. Griffin. (2009) FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resistance Updates 12:3, pages 81-89.
Crossref
Crossref
Wen-Chung ShiehJoe McKennaJoseph A. SclafaniSong XueMichael GirgisJames ViveloBranko RadetichKapa Prasad. (2008) Syntheses of a Triad of Flt3 Kinase Inhibitors: From Bench to Pilot Plant. Organic Process Research & Development 12:6, pages 1146-1155.
Crossref
Crossref